EGFR and endometrial cancer: Both inhibitors blocked estrogen-mediated nuclear accumulation of the PH-RFP reporter, indicating a requirement for both HB-EGF and EGFR in estrogen-mediated PI3K activation in Hec50 endometrial cancer cells.